Home
  • Donate money to KEI
  • Listserves
  • Main Areas of Work
  • Events
  • Publications
  • Blogs
  • About KEI

Knowledge Ecology International

Attending and mending the knowledge ecosystem

Navigation

  • Site Map
  • Recent posts
  • Feed aggregator
  • Polls
  • Groups

Round II of the Paris Accord took place in Paris on October 23 and 24, 2009.

Book navigation

  • Right to Read for Persons with Reading Disabilities
  • About KEI
  • Access to Medical Technologies
  • Berne Convention Appendix Regarding Special Provisions Regarding Developing Countries
  • Competition Policy
  • Data points on prices of medical technologies
  • Databases
  • Enforcement and Remedies to Infringement
  • Events
  • General Access to Knowledge Issues
  • Government Funded Inventions
  • Knowledge Governance Fora
  • Main Areas of Work
  • Medical diseases, conditions and technologies
  • Nuclear Proliferation
  • Patent Policy
  • Prizes to stimulate innovation
  • Publications and Research Notes
  • Test Data
  • Timelines
  • Transparency

User login

What is OpenID?
  • Log in using OpenID
  • Cancel OpenID login
  • Create new account
  • Request new password
Home

Polls

  • Which IPR Trade Agreement is the worst? - 117 votes - open
  • What best describes Obama Administration rationale for secrecy of tabled TransPacific Partnership Agreement IPR texts? - 144 votes - open
  • Why does Bill Gates oppose discussions of a medical R&D treaty at the World Health Organization? - 245 votes - closed
  • Which IPR norm setting forum is the LEAST transparent - 100 votes - closed
  • Can the U.S. realistically honor commitments to fund treatment for AIDS in developing countries without generic products? - 388 votes - closed
  • Why would a government oppose a WIPO Treaty to expand access for persons with disabilities? - 79 votes - closed
  • Why does the Obama Administration insist on secrecy of the draft Anti-Counterfeiting Trade Agreement (ACTA) text? - 277 votes - closed
  • The Obama Administration support for a pro-consumer Biosimilars Pathway is: - 40 votes - closed

Support KEI

WASHINGTON 1621 Connecticut Ave. NW, Suite 500, Washington, DC 20009 /TEL: +1.202.332.2670 · FAX +1.202.332.2673 GENEVE 1 Route des Morillons, CP 2100, 1211 Genève 2, Switzerland TEL: +41.22.791.6727
THEME DESIGN Copyright © 2009 under GPL by Tribute Media. Site Powered by Drupal.